1984
DOI: 10.1136/jcp.37.5.523
|View full text |Cite
|
Sign up to set email alerts
|

Antithrombin III metabolism in patients with liver disease.

Abstract: SUMMARY Liver diseases are associated with complex haemostasis defects, in which platelets, coagulation, and fibrinolysis may all be affected. The low plasma concentrations of clottinlg factors often found can be the result of many changes such as impaired synthesis, increased catabolism due to intravascular coagulation, or alternate distribution.In this study, we investigated the metabolism of purified human antithrombin III(AT III) labelled with 125I in 25 patients with histologically established liver disea… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
28
0
1

Year Published

1989
1989
2016
2016

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 44 publications
(30 citation statements)
references
References 32 publications
1
28
0
1
Order By: Relevance
“…Depletion of AT III levels during sepsis may partly be the result of a decreased synthe sis [27], increased catabolism due to intravas cular coagulation [28,29] or to an alternate distribution [30]. Albumin is synthesized in the liver and the molecular weight of AT III and albumin is similar.…”
Section: Discussionmentioning
confidence: 99%
“…Depletion of AT III levels during sepsis may partly be the result of a decreased synthe sis [27], increased catabolism due to intravas cular coagulation [28,29] or to an alternate distribution [30]. Albumin is synthesized in the liver and the molecular weight of AT III and albumin is similar.…”
Section: Discussionmentioning
confidence: 99%
“…The GSA-Rmax in hepatocytes was shown to strongly Receptor-binding radiopharmaceuticals provide an opporcorrelate with conventional liver function tests, especially tunity to conduct analytic measurements of a specific interacwith validated indicators of hepatic functional capacity such tion within a normal physiological environment. 15,16 Radiolaas antithrombin III, 25 fibrinogen, 26 and ICGR15. The GSAbeled ASGP was originally developed by Vera et al 17 Tc-GSA Rmax represented both the initial and recycled number of is a similar compound but was developed independently for receptors since the first 30-min period was selected as the use in clinical use.…”
Section: Discussionmentioning
confidence: 99%
“…Liver disease is often associated with hemostatic abnormalities such as decreased plasma levels of coagulation factors and inhibitors [ 1,2], dysfibrinogenemia [3 -61, thrombocytopenia, platelet dysfunction, and disseminated intravascular coagulation (DIC) 17-91. In addition, accelerated fibrinolysis has long been recognized .…”
Section: Introductionmentioning
confidence: 99%